Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Brainstorm Cell Therapeutics Inc BCLI

Healthcare Biotechnology
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BCLI)

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

PR Newswire 2 days ago

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

PR Newswire 8 days ago

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

PR Newswire 9 days ago

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

PR Newswire 10 days ago

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

PR Newswire 11 days ago

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

PR Newswire April 1, 2024

BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference

PR Newswire February 27, 2024

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS

PR Newswire February 23, 2024

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Accesswire February 18, 2024
View More News ››

Opinion & Analysis (NDAQ:BCLI)

Time to go long on BrainStorm Cell Therapeutics?

The Life Sciences Report January 18, 2017

Embrace low-cap biotech for high gains: Eden Rahim of Next Edge Capital

The Life Sciences Report March 2, 2016

Yamana Gold (T.YRI) responds to assessment in Argentine legal dispute

Stockhouse Editorial January 2, 2015
View More Opinion ››

Bullboard Posts (NDAQ:BCLI)

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ

JUST IN: $BCLI BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleBrainStorm Cell Therapeutics Regains...
whytestocks - 7 days ago

BrainStorm Cell Therapeutics Announces Peer-reviewed Publica

BREAKING NEWS: $BCLI BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's&#xAE...
whytestocks - 8 days ago

BrainStorm Cell Therapeutics Submits Special Protocol Assess

News; $BCLI BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn&#xAE;...
whytestocks - February 23, 2024

BCLI....Halted

BrainStorm Cell Therapeutics Stock Trading Halted Today 2023-09-27 04:00 ET - News Release NEW YORK
Iseneschal - September 27, 2023

BCLI - ALS Parkinson's Potential Cure

Right now we are waiting for Tuesday April 21, 2015 results of the trial Phase 2a study.  Here is what was covered in their January...
semismart1 - April 16, 2015

Does BrainStorm Cell Therapeutics (OTCBB: BCLI) Ha

While BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced on Tuesday their intention to sell 19.8 million shares of their...
box532 - July 18, 2012
View more Bullboard ››

Geologica Resource Corp.

Geologica Resource Corp.

Geologica Resource Corp. is an exploration and development company focused on the acquisition, exploration and development of ...
View More »